Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
NCT07091734 on ClinicalTrials.gov · last registry update 2025-09-09
A small phase 2 — 32 participants, against a typical 110. Due to report September 2029, alongside 12 other tracked readouts that quarter. Primary outcome, as filed: Change in Body Mass Index (BMI) from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P2
- Drug
- tirzepatideMounjaro, Zepbound
- Sponsor
- University of Michigan
- Sponsor type
- Other
- Enrollment
- 32
- Started
- 2025-09-08
- Primary completion
- 2029-09 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in Body Mass Index (BMI) from baseline in Group A (Tirzepatide-treated) versus Group B (control) at 24 weeks
Conditions studied
Lipodystrophy, Partial
Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.